OMNARIS Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Omnaris, and when can generic versions of Omnaris launch?
Omnaris is a drug marketed by Covis and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has fourteen patent family members in twelve countries.
The generic ingredient in OMNARIS is ciclesonide. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ciclesonide profile page.
DrugPatentWatch® Generic Entry Outlook for Omnaris
Omnaris was eligible for patent challenges on October 20, 2010.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 1, 2028. This may change due to patent challenges or generic licensing.
There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OMNARIS?
- What are the global sales for OMNARIS?
- What is Average Wholesale Price for OMNARIS?
Summary for OMNARIS
International Patents: | 14 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 66 |
Clinical Trials: | 8 |
Patent Applications: | 4,217 |
Drug Prices: | Drug price information for OMNARIS |
What excipients (inactive ingredients) are in OMNARIS? | OMNARIS excipients list |
DailyMed Link: | OMNARIS at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for OMNARIS
Generic Entry Date for OMNARIS*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SPRAY, METERED;NASAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for OMNARIS
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 2/Phase 3 |
Takeda | Phase 3 |
AstraZeneca | Phase 3 |
Paragraph IV (Patent) Challenges for OMNARIS
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
OMNARIS | Nasal Spray | ciclesonide | 50 mcg | 022004 | 1 | 2012-02-13 |
US Patents and Regulatory Information for OMNARIS
OMNARIS is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of OMNARIS is ⤷ Subscribe.
This potential generic entry date is based on patent ⤷ Subscribe.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Covis | OMNARIS | ciclesonide | SPRAY, METERED;NASAL | 022004-001 | Oct 20, 2006 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OMNARIS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Covis | OMNARIS | ciclesonide | SPRAY, METERED;NASAL | 022004-001 | Oct 20, 2006 | ⤷ Subscribe | ⤷ Subscribe |
Covis | OMNARIS | ciclesonide | SPRAY, METERED;NASAL | 022004-001 | Oct 20, 2006 | ⤷ Subscribe | ⤷ Subscribe |
Covis | OMNARIS | ciclesonide | SPRAY, METERED;NASAL | 022004-001 | Oct 20, 2006 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for OMNARIS
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Boehringer Ingelheim Vetmedica GmbH | Aservo EquiHaler | ciclesonide | EMEA/V/C/004991 For the alleviation of clinical signs of severe equine asthma (formerly known as Recurrent Airway Obstruction – (RAO), Summer Pasture Associated Recurrent Airway Obstruction – (SPA-RAO)). |
Authorised | no | no | no | 2020-01-28 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for OMNARIS
See the table below for patents covering OMNARIS around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 2004271744 | Use of ciclesonide for the treatment of respiratory diseases | ⤷ Subscribe |
New Zealand | 501950 | Medicinal compositions for application to mucosa | ⤷ Subscribe |
Colombia | 5251406 | UNA COMPOSICION FARMACEUTICA ACUOSA EN FORMA DE DISPERSION QUE CONTIENE CICLESONIDA E HIDROXIPROPILMETILCELULOSA QUE PRESENTA ESTABILIDAD MEJORADA DURANTE SU PRODUCCION | ⤷ Subscribe |
>Country | >Patent Number | >Title | >Estimated Expiration |
OMNARIS Market Analysis and Financial Projection Experimental
More… ↓